You are here

Prevention of Children's Tympanostomy Tube Otorrhea

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DC014416-01
Agency Tracking Number: R43DC014416
Amount: $159,277.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDCD
Solicitation Number: PA14-071
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2285 EAST FOOTHILL BLVD
PASADENA, CA 91107-3658
United States
DUNS: 800316361
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 WILLIAM SLATTERY
 (626) 844-1906
 wslattery@oraypharma.com
Business Contact
 ERIK PIERSTORFF
Phone: (626) 844-1906
Email: epierstorff@oraypharma.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Otitis media (infection of the middle ear space) is one of the most common diseases of childhood. Myringotomy with tympanostomy tube (TT) insertion is the most common operation performed on children in the United States. Otorrhea is the most common complication following tube insertion and can occur in up to 17% of ears receiving TT and is often associated with active infection. Current treatments involve the administration of antibiotic or antibiotic/steroid drops twicea day for 14 days. Though this decreases the incidence of infection, there are issues with patient compliance and temporary conductive hearing loss in the children. An enhanced treatment option would improve treatment efficacy, increase patient compliance, and eliminate the temporary hearing loss. This Phase I SBIR proposal involves the fabrication of therapeutic treatments for otitis media associated with tympanostomy tubes in children. The specific aims of this proposal present a roadmap towards the

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government